StockData

Lantheus vs Neogen

LNTH and NEOG side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LNTH and NEOG compare

Lantheus is the larger company, worth 2.8 times as much as Neogen ($6.6B against $2.4B).

Lantheus grew revenue faster over the last twelve months (2.3% versus −0.33% for Neogen).

Lantheus keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with −6.3% at Neogen.

Lantheus scores higher on the StockData Score (11 against 7 for Neogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLNTHNEOG
Size and price
Market cap$6.6B$2.4B
Share price$101.72$10.88
Change, 1 year91.5%70.8%
Change, 5 years265%−73.6%
Beta (5Y)0.410.86
Employees1,1932,636
StockData Score
Total score11 (better)7
Valuation score01 (better)
Growth score22
Performance score5 (better)3
Health score4 (better)1
Dividend score00
Valuation
P/E24.6×–
P/S4.3×2.7× (better)
P/B5.1×1.1× (better)
EV/EBITDA16.9× (better)34.5×
P/FCF–47.7×
PEG0.24–
FCF yield–2.1%
Fair value$91.21$7.30
Margin of safety−11.5% (better)−49.0%
Growth
Revenue growth (TTM)2.3% (better)−0.33%
Revenue growth, 5Y average35.3% (better)13.2%
Net income growth (TTM)1.6%–
EPS growth (TTM)9.5%–
Profitability
Gross margin60.1% (better)47.4%
Operating margin19.4% (better)−0.83%
Net margin17.7% (better)−6.3%
FCF margin–5.6%
Return on equity22.2% (better)−2.7%
Return on invested capital19.7% (better)−0.17%
Financial health
Debt / equity0.44 (better)0.74
Net debt / EBITDA−0.0612.69 (better)
Interest coverage15.3×–
Current ratio3.063.90 (better)
Altman Z-score5.52 (better)1.35
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions117%109%
Held by insiders2.3%0.60%
Insider net buying, 12 months–−$102K
Short interest, % of float5.7%5.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.